Do You or Someone You Love Have Alzheimer's Disease?
​
Consider Participating in the SPRING Trial
SPRING is a clinical trial evaluating whether
the investigational oral drug LHP588 is safe and can halt or slow the progression of Alzheimer's disease by reducing the damage caused by bacteria in the brain. Eligible study participants with mild to moderate Alzheimer's are being recruited at study sites around the United States.
A Revolutionary New Approach to Treating Alzheimer's
The SPRING Trial is based on the growing body of scientific evidence that the bacteria P. gingivalis associated with gum disease, can infect the brain and cause Alzheimer's disease. LHP588 is an investigational drug designed to inactivate the toxic enzymes produced by the bacteria and stop or slow further damage to healthy brain cells.
You or a loved one may be eligible for the study if you:
-
Are 55 to 80 ears old
-
Have been diagnosed with mild to moderate Alzheimer's disease
​ -
Have a caregiver or family member who will attend study visits, report on daily activities, and oversee study medication
​ -
The presence of a P. gingivalis infection will be tested by a saliva test on the first visit.
The SPRING trial is supported by the National Institute on Aging of the National Institutes of Health under Award Number R01AG088524. The content of this website is the responsibility of Lighthouse Pharmaceuticals and does not necessarily represent the views of the National Institutes of Health.
​
The safety and effectiveness of LHP588 for the treatment of Alzheimer's disease has not yet been established.
